Meet the Team

Management

 

Dr. Nancy Chang, CEO

Nancy T. Chang, Ph.D. has served as a Director at Ansun since 2011. Since 2007, Dr. Chang has served as the President of Apex Enterprises, Inc., an investment management company with a major focus on healthcare investments. From 2007 to 2012, she was the Chairperson and Senior Managing Director of Caduceus Asia Partners at OrbiMed Advisors L.L.C. From 1987 to 2007, Dr. Chang served as Co-Founder, President and Chairman of Tanox, Inc., which was sold to Genentech in 2007. Prior to founding Tanox, Dr. Chang held several leadership positions at Centocor, now a division of Johnson & Johnson. She was also an Associate Professor at Baylor College of Medicine, and before that, she worked at the Roche Institute of Molecular Biology. She has served on the boards of a number of companies, including Charles River Laboratories International, Inc., Applied Optoelectronics Inc. and is currently a member of the board of directors of SciClone Pharmaceuticals, Inc. In addition, Dr. Chang was a member of the board of directors at the Biotechnology Industry Organization (BIO) and BioHouston. Dr. Chang also was a Director at the Federal Reserve Bank in the Dallas Houston Branch, and was a Director for Project Hope. She has published more than 35 papers on topics ranging from monoclonal antibodies to HIV and holds seven patents. Dr. Chang received her Doctorate in Biological Chemistry from Harvard University.

 

Dr. George Wang, CTO

George Y. Wang, Sc.D. has served as Senior Technical Advisor and then Chief Technical Officer at Ansun Biopharma since April 2014.  He was the Managing Director  ofA-Bio Pharma Pte Ltd in charge of all operations from 2004 until 2008.  Prior to that, he was at Tanox, Inc. from 1991 until 2002 and served as Vice President of Process Development and Production.  Dr. Wang held various engineering positions at IDEC Pharmaceuticals, BP Amoco Corporation and MGI Pharmaceuticals, Inc.  Dr. Wang received his Sc.D. in Biochemical Engineering from Massachusetts Institute of Technology.

 

Mikael Havluciyan, Senior V.P. of Operations, General Counsel

Mike Havluciyan has served as V.P., General Counsel of Ansun since 2009, and recently became Ansun’s Senior V.P. of Operations and General Counsel.  Prior to Ansun, Mr. Havluciyan initially served as Director of Intellectual Property at Nanogen, Inc. and was subsequently promoted to Associate General Counsel.  From 1998-2006, he was an associate first at Lyon & Lyon and then Fish & Richardson, specializing in intellectual property law, with a particular emphasis in counseling life science companies.  Mr. Havluciyan received a B.S. in Biology from the University of California, Irvine and his law degree from Loyola Law School, where he was a Note and Comment Editor and published author on the Loyola of Los Angeles Entertainment Law Journal.  Mr. Havluciyan has been a member of the California Bar since 1998 and the Patent Bar since 1999.

 

Dr. Jennifer Ho, V.P. of Clinical Development

Dr. Ho joined Ansun in 2017 as its V.P. of Clinical Development.  She is also the V.P. of R&D and Clinical Trial Development at Steminent US, Inc., which is a company involved in stem cell therapeutics.  She has a long list of accomplishments and awards including: being a Professor at the Graduate Institute of Clinical Medicine, Taipei Medical University; a Director of Medical Research at the Wan Fang Medical Center, Taipei Medical University, Taiwan; being an editorial board member or review on over 10 scientific journals; receiving the Best Clinical Research Award from Taipei Medical University four out of the last seven years; and having 6 patents and publishing over 40 peer reviewed scientific publications.  She received her M.D. in 1998 from National Taiwan University and her Ph.D. in Biopharmaceutical Science from the Institute of Biopharmaceutical Science, National Yang-Ming University.

 

Jeff Lumin, CFO and VP of Business Development

Before joining Ansun, Jeff worked as a research analyst and fund manger at Franklin Templeton and at AIG global equity team, in New York and at the investment division of CITIC Securities, the largest investment bank in China. He is a veteran investor in the global healthcare industry, with over a decade of experience investing in early stage life science companies, where innovative, breakthrough new medicines were successfully developed and commercialized. Jeff received his MBA from Yale School of Management, and M.S. and M. Phil. degrees from Yale School of Medicine.

 

Board of Directors


Allen Chao

Allen Chao, Ph.D. has served as a Director at Ansun since 2010.  Since January 2008, Dr. Chao has been Chairman of Newport Healthcare Advisors, LLC, a healthcare investment management and consulting company.  Dr. Chao was a co-founder of Watson Pharmaceuticals, Inc. (now Actavis plc), a specialty pharmaceutical company, serving as a director from 1985 to May 2008, Chairman of the board of directors from May 1996 to May 2008, and Chief Executive Officer from 1985 to September 2007. While at Watson, Dr. Chao oversaw the company’s growth, through internal R&D, licensing and acquisitions of pharmaceutical products and technologies, as well as mergers and acquisition activities. Dr. Chao received a Ph.D. in industrial and physical pharmacy from Purdue University in 1973. In May of 2000, he received the degree of Doctor of Science from Purdue.

Nancy Chang

Nancy T. Chang, Ph.D. has served as a Director at Ansun since 2011. Since 2007, Dr. Chang has served as the President of Apex Enterprises, Inc., an investment management company with a major focus on healthcare investments. From 2007 to 2012, she was the Chairperson and Senior Managing Director of Caduceus Asia Partners at OrbiMed Advisors L.L.C. From 1987 to 2007, Dr. Chang served as Co-Founder, President and Chairman of Tanox, Inc., which was sold to Genentech in 2007. Prior to founding Tanox, Dr. Chang held several leadership positions at Centocor, now a division of Johnson & Johnson. She was also an Associate Professor at Baylor College of Medicine, and before that, she worked at the Roche Institute of Molecular Biology. She has served on the boards of a number of companies, including Charles River Laboratories International, Inc., Applied Optoelectronics Inc. and is currently a member of the board of directors of SciClone Pharmaceuticals, Inc. In addition, Dr. Chang was a member of the board of directors at the Biotechnology Industry Organization (BIO) and BioHouston. Dr. Chang also was a Director at the Federal Reserve Bank in the Dallas Houston Branch, and was a Director for Project Hope. She has published more than 35 papers on topics ranging from monoclonal antibodies to HIV and holds seven patents. Dr. Chang received her Doctorate in Biological Chemistry from Harvard University.

Michael Chang

Dr. Michael Chang – Chairman of OBI, also the director Amaran as well as the founder of both Optimer Pharmaceuticals and OBI. In 1994, Dr. Chang
established Pharmanex, a health products company, which was acquired by NuSkin Enterprises, where he was appointed Chief Scientific Advisor.
Prior to this, he founded Cinogen in 1993. Dr. Chang was formerly the Director of Medical Chemistry at Rhone-Poulenc Rorer and Deputy Director
of Medicinal Chemistry at Merck, Sharpe & Dohme (US Merck). Dr. Chang received his Ph.D. in Organic Chemistry from Brandeis University, and
conducted postdoctoral research at MIT. He received his BS in Chemistry from Fu Jen Catholic University in Taiwan. He holds 39 patents and has
published more than 69 scientific papers in peer reviewed journals.